Holen Sie sich die Stockscreener-App
6.23
3.11%
-0.20
Handel nachbörslich:
6.37
0.14
+2.25%
Schlusskurs vom Vortag:
$6.43
Offen:
$6.39
24-Stunden-Volumen:
716.67K
Relative Volume:
0.39
Marktkapitalisierung:
$427.62M
Einnahmen:
$11.40B
Nettoeinkommen (Verlust:
$-95.73M
KGV:
-2.5429
EPS:
-2.45
Netto-Cashflow:
$-64.37M
1W Leistung:
+7.97%
1M Leistung:
-8.11%
6M Leistung:
+2.98%
1J Leistung:
-26.88%
1-Tages-Spanne:
$6.18
$6.41
1-Wochen-Bereich:
$5.51
$6.4399
52-Wochen-Spanne:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
Firmenname
Mind Medicine Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MNMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.23 | 427.62M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Mind Medicine Inc Aktie (MNMD) Neueste Nachrichten
Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Mind Medicine (MNMD): Good Data, But Psychedelic Stigma Clouds Investor Confidence - Seeking Alpha
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance
Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus
MindMed Announces New Employee Inducement Grants - Business Wire
Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa
MNMD Stock Forecast From 2025 To 2040 - Exla Resources
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com India
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan
MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com
MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India
What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World
Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World
Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World
Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider
Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India
Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
Mind Medicine Inc (MNMD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
MindMed Advances Clinical Trials and Strengthens Financial Position - TipRanks
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months - MSN
Finanzdaten der Mind Medicine Inc-Aktie (MNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mind Medicine Inc-Aktie (MNMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer |
Mar 25 '25 |
Sale |
6.74 |
6,836 |
46,075 |
446,177 |
| Sullivan Mark | Chief Legal Officer |
Mar 25 '25 |
Sale |
6.74 |
6,576 |
44,322 |
316,621 |
| Liao Carrie | Chief Accounting Officer |
Mar 25 '25 |
Sale |
6.74 |
2,347 |
15,819 |
144,923 |
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):